H-T. Arkenau

659 total citations
29 papers, 385 citations indexed

About

H-T. Arkenau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, H-T. Arkenau has authored 29 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in H-T. Arkenau's work include Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (7 papers). H-T. Arkenau is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (7 papers). H-T. Arkenau collaborates with scholars based in United Kingdom, United States and Spain. H-T. Arkenau's co-authors include Richard Kefford, Georgina V. Long, E.P. Hamilton, István Takács, Anja von Heydebreck, L. Dirix, Kevin M. Chin, Guy Jérusalem, Petros Nikolinakos and Valentina Boni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

H-T. Arkenau

28 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H-T. Arkenau United Kingdom	9	299	152	102	74	61	29	385
Laura Kirby Australia	8	245 0.8×	169 1.1×	128 1.3×	36 0.5×	33 0.5×	11	362
Christine Longvert France	12	353 1.2×	233 1.5×	59 0.6×	106 1.4×	40 0.7×	34	525
Anton Safonov United States	7	321 1.1×	127 0.8×	134 1.3×	110 1.5×	135 2.2×	36	451
Andrew Elliott United States	10	260 0.9×	191 1.3×	146 1.4×	54 0.7×	89 1.5×	99	483
Yann Bergé France	10	162 0.5×	154 1.0×	100 1.0×	47 0.6×	37 0.6×	17	323
Yu Kataoka Japan	6	176 0.6×	213 1.4×	99 1.0×	43 0.6×	50 0.8×	10	378
Hidejiro Torigoe Japan	13	216 0.7×	242 1.6×	186 1.8×	35 0.5×	108 1.8×	28	450
Nicole Drezner United States	8	233 0.8×	160 1.1×	218 2.1×	29 0.4×	73 1.2×	13	430
Tao Osgood United States	6	185 0.6×	158 1.0×	58 0.6×	27 0.4×	43 0.7×	14	308
Andrée Rorive Belgium	12	197 0.7×	114 0.8×	107 1.0×	32 0.4×	34 0.6×	49	344

Countries citing papers authored by H-T. Arkenau

Since Specialization

Citations

This map shows the geographic impact of H-T. Arkenau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H-T. Arkenau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H-T. Arkenau more than expected).

Fields of papers citing papers by H-T. Arkenau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H-T. Arkenau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H-T. Arkenau. The network helps show where H-T. Arkenau may publish in the future.

Co-authorship network of co-authors of H-T. Arkenau

This figure shows the co-authorship network connecting the top 25 collaborators of H-T. Arkenau. A scholar is included among the top collaborators of H-T. Arkenau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H-T. Arkenau. H-T. Arkenau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oh, D-Y., H-T. Arkenau, Josep Tabernero, et al.. (2023). 139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1526–S1527. 3 indexed citations

Patel, Minesh, et al.. (2022). 453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study. Annals of Oncology. 33. S744–S745. 31 indexed citations

Arkenau, H-T., et al.. (2022). 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology. 33. S875–S875. 16 indexed citations

Berton-Rigaud, Dominique, Giuseppe Curigliano, Renaud Sabatier, et al.. (2022). 549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study. Annals of Oncology. 33. S799–S800.

Hamilton, E.P., Charles L. Shapiro, Valentina Boni, et al.. (2022). 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer. Annals of Oncology. 33. S196–S196. 31 indexed citations

Davar, Diwakar, Randy F. Sweis, George Blumenschein, et al.. (2021). 91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein. Annals of Oncology. 32. S1411–S1413. 5 indexed citations

Piccart, Martine, Manuel Ruíz Borrego, H-T. Arkenau, et al.. (2021). 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Annals of Oncology. 32. S478–S479. 4 indexed citations

Hollebecque, Antoine, John Bridgewater, Funda Meric‐Bernstam, et al.. (2021). 52P Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA). Annals of Oncology. 32. S378–S379. 3 indexed citations

Howell, Sacha J., Matthew Krebs, Simon Lord, et al.. (2021). 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Annals of Oncology. 32. S477–S478. 7 indexed citations

10.

Johnson, Magnus L., Ira Winer, H-T. Arkenau, et al.. (2021). 542P Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours. Annals of Oncology. 32. S606–S607. 4 indexed citations

11.

Arkenau, H-T., Troy H. Guthrie, Tarek Mekhail, et al.. (2021). 643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors. Annals of Oncology. 32. S671–S672. 2 indexed citations

12.

Bulat, Iurie, H-T. Arkenau, Richard D. Baird, et al.. (2020). 278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients. Annals of Oncology. 31. S351–S352. 4 indexed citations

13.

Piccart, Martine, Manuel Ruíz Borrego, François P. Duhoux, et al.. (2020). 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC). Annals of Oncology. 31. S386–S386. 2 indexed citations

14.

Vergote, Ignace, Emma Dean, Ulrik Lassen, et al.. (2017). A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Annals of Oncology. 28. v330–v331. 6 indexed citations

15.

Telli, Melinda L., Simon Lord, Emma Dean, et al.. (2017). Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792). Annals of Oncology. 28. v76–v76. 3 indexed citations

16.

Falchook, Gerald S., Manish R. Patel, J. R. Infante, et al.. (2017). Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel. Cancer Research. 77(4_Supplement). P6–11. 14 indexed citations

17.

Kelly, Karen, J. R. Infante, Nicholas Iannotti, et al.. (2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial. Open Repository and Bibliography (University of Liège). 1 indexed citations

18.

Olmos, David, Denis Lacombe, Roger A’Hern, et al.. (2012). Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. British Journal of Cancer. 107(7). 1025–1030. 12 indexed citations

19.

Arkenau, H-T., Richard Kefford, & Georgina V. Long. (2010). Targeting BRAF for patients with melanoma. British Journal of Cancer. 104(3). 392–398. 111 indexed citations

20.

Porschen, Rainer, H-T. Arkenau, Stefan Kubicka, et al.. (2005). Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): Results of an interim safety and efficacy analysis. Zeitschrift für Gastroenterologie. 43(5). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact